8,168 Shares in IQVIA Holdings Inc. (NYSE:IQV) Acquired by Magnetar Financial LLC

Magnetar Financial LLC bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor bought 8,168 shares of the medical research company’s stock, valued at approximately $2,066,000.

Several other large investors have also recently added to or reduced their stakes in the business. Mutual Advisors LLC acquired a new position in IQVIA during the 4th quarter worth approximately $217,000. HB Wealth Management LLC grew its holdings in IQVIA by 38.7% during the 4th quarter. HB Wealth Management LLC now owns 2,202 shares of the medical research company’s stock worth $509,000 after acquiring an additional 614 shares in the last quarter. CVA Family Office LLC acquired a new position in IQVIA during the 4th quarter worth approximately $43,000. Great Lakes Retirement Inc. grew its holdings in IQVIA by 5.2% during the 4th quarter. Great Lakes Retirement Inc. now owns 2,309 shares of the medical research company’s stock worth $534,000 after acquiring an additional 115 shares in the last quarter. Finally, Good Life Advisors LLC acquired a new position in IQVIA during the 4th quarter worth approximately $210,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

Shares of NYSE:IQV traded up $7.38 during trading on Friday, hitting $239.67. 1,195,238 shares of the stock were exchanged, compared to its average volume of 1,420,984. The company has a fifty day moving average price of $220.23 and a two-hundred day moving average price of $229.46. The company has a market cap of $43.69 billion, a PE ratio of 32.74, a P/E/G ratio of 2.26 and a beta of 1.49. The company has a current ratio of 0.85, a quick ratio of 0.88 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping the consensus estimate of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The business had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. During the same quarter in the previous year, the company earned $2.22 EPS. The company’s quarterly revenue was up 2.3% on a year-over-year basis. On average, analysts forecast that IQVIA Holdings Inc. will post 10.21 EPS for the current year.

Analyst Ratings Changes

IQV has been the subject of several analyst reports. The Goldman Sachs Group initiated coverage on shares of IQVIA in a report on Thursday, June 6th. They set a “buy” rating and a $270.00 price target for the company. UBS Group upped their target price on shares of IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Barclays upped their target price on shares of IQVIA from $255.00 to $275.00 and gave the company an “overweight” rating in a report on Tuesday, July 23rd. Jefferies Financial Group cut shares of IQVIA from a “buy” rating to a “hold” rating and lowered their target price for the company from $266.00 to $242.00 in a report on Wednesday. Finally, Truist Financial upped their target price on shares of IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Four investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $263.56.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.